通心络胶囊治疗不稳定性心绞痛的Cochrane系统评价的研究方案(英文)

A Cochrane systematic review protocol of Tongxinluo capsule for unstable angina pectoris

背景 通心络胶囊由 5种虫类中药组成 ,主要用于心脑血管疾病。它于 2 0 0 0年获得国家科技进步二等奖 ,并被列入国家中药基本药物。目的 评价通心络胶囊治疗不稳定心绞痛的疗效和可能的副效。检索策略 电子检索TheCochraneHeartReviewGroupspecialisedtrialsregister,TheCochraneControlledTrialsRegister,publishedinthelatestissueoftheCochraneLibrary ,MEDLINE ,EMBASE ,CBM ,ChineseCochraneCentreControlledTrialsRegister,CurrentCon trolledTrials (www .controlled -trials.com) ,TheNationalResearchRegister。 手检 我国 83种中医药杂志。资料纳入标准 使用通心络胶囊治疗不稳定性心绞痛的随机和半随机对照试验。结果测量指标为因急性心肌梗死所致的死亡、心绞痛的严重程度、急性心绞痛发作次数、心电图改善程度、硝酸甘油用量和症状改善 ,等等。资料分析 对符合纳入标准的随机对照试验进行内部真实性评价 ,如果所有纳入的随机对照试验有足够的质量和相似性 ,则采用Meta分析。

Background Tongxinluo capsule is a new drug for cardio-cerebral vascular diseases on the national essential drug list of China, and the second-class award of National Science and Technology Development of China, 2001. Objective This review aims to assess the effect (harms and benefits) of Tongxinluo capsule for unstable angina. Search strategy electronic searchs The Cochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register, published in the latest issue of the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese Cochrane Centre Controlled Trials Register, Current Controlled Trials (www.controlled-trials.com), The National Research Register Handsearchs We will search 83 journals of Chinese traditional medicine.Inclusion riteria We will include randomised controlled trials of Tonxinluo capsule versus placebo or other current phamarcotherapy or other Chinese medicinal herbs in the participants with unstable angina pectoris. Studies will report mortality (sudden death from acute myocardial infarction), severity of angina pectoris, frequency of acute attack angina, ECG improvement, rate of dosage reducing or taking frequency of nitroglycerine and symptom improvement, etc. Data analysis Data will be included in a meta-analysis if they are available, of sufficient quality and sufficiently similar.